Check out which companies are making headlines before the bell Thursday:
There has been "clear improvement" in the economic situation in Europe over the past year, European Central Bank policymaker Ewald Nowotny told CNBC.
Thomas Watjen, President & CEO of Unum, discusses the "high level" issues facing many consumers living paycheck to paycheck, and the difficulty getting adequate insurance coverage.
Christian Thwaites, Sentinel Investments; and Mark Vitner, Wells Fargo Securities, provide perspective on the markets and economy, despite the looming sequester and political unrest in Italy.
CNBC's Kelly Evans reports political fallout from the Italian election produced name-calling from Germany and is causing problems in European policymaking.
CNBC's Kelly Evans tells you what the markets will be watching as we approach the start of trading in the U.S. (1:19)
C.H. Robinson Worldwide pulled back to support yesterday, and the bulls piled in.
Mylan's aquisition of Agila is expected to double its business. Heather Bresch, Myland CEO, offers insight.
The latest on the sequester, with Richard Socarides strategist, and Dick Morris, former Clinton advisor.
Have conservatives dissed Chris Christie? Star Parker, Cure founder & president, and Al Cardenas, American Conservative, discuss.
Carl Hess, Global Head of Investment at Towers Watson, says equities are reasonably valued at this point, but that weak economic fundamentals still hold a long-term sway over the markets.
J.C. Penney delivered the latest dismal retail news, reporting a much larger-than-expected loss as same-store sales fell 32 percent. Shares skidded after-hours.
Mad Money host Jim Cramer explains how not to get drawn into poor investing ideas.
If your portfolio is awash in red marks and minus signs, perhaps you’re making this mistake.
Looking to speculate in biopharma stocks? Cramer's done some homework and he likes this one.
Alkermes is a pharmaceutical company with a portfolio of over 20 commercial drug products. Richard F. Pops, Alkermes CEO, weighs in.
You say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.
The Mad Money host was talking about the 12th largest independent oil and gas exploration and production company.
Mark E. Ellis, Linn Energy chairman, president & CEO, says his company's hedges allow them to take very little commodity price risk.
Aria uses structure-based drug design to identify molecules able to overcome resistance in therapy. Dr. Harvey Berger, Aria Pharmaceuticals chairman & CEO, offers insight on earnings.